eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its...

eBioscience Corporation Announced Today That James Glynn Has Been Appointed to
Its Board of Directors, Effective April 15, 2008

SAN DIEGO, April 15 /PRNewswire/ -- Mr. Glynn has over 34 years of
combined financial, operating and director level experience, and is well known
within the life sciences industry for his role in the growth and development
of several biotechnology companies. Most notably, Mr. Glynn retired from
Invitrogen Corporation (Nasdaq: IVGN) in 2003 where, during his tenure with
the company, he held several operating roles including CFO, President and COO
and CEO. During this time, Mr. Glynn led the company through several stages of
growth including an IPO, numerous financings and several acquisitions
including Novex, GIBCO Life Technologies, Research Genetics and Molecular
Probes. Mr. Glynn, following his retirement from Invitrogen Corporation,
remained on the company's board of directors until April 2006.
"We are very pleased to be adding someone of Jim's reputation and
experience to our board," said Todd R. Nelson Ph.D., eBioscience's Chief
Executive Officer. "As an emerging global leader in the cellular analysis
market, we are focused on growing our business operations through the
development and commercialization of a diverse array of products, and also
through the operational execution of several key strategic initiatives. In
his role as director, Mr. Glynn will provide invaluable operating insight,
financial advice and strategic guidance to ensure eBioscience remains a leader
in the life sciences market place." Brian Seed Ph.D., Chairman of the board
of directors for eBioscience added, "We look forward to tapping Jim's wealth
of operating wisdom and the insights gleaned from his decades of senior
management experience in the life science and related industries. Jim enjoys
an enviable reputation among investors and professional fund managers for his
business insight, strategic acumen, and proven ability to contribute guidance
at the board level."
Prior to joining Invitrogen Corporation in 1998 as the company's CFO, Mr.
Glynn served as CFO for Matrix Pharmaceutical, Inc. from 1995 to 1998 and as
CFO for Mycogen Corporation from 1987 to 1995. Prior to that he was Vice
President, Finance & Treasurer of Lubrizol Enterprises, Inc. and an Audit
manager for Price Waterhouse & Co. from 1974 to 1982.
Mr. Glynn currently serves as a director for Alphatec Spine, Inc. and
American Specialty Health.
SOURCE eBioscience Corporation

Noosheen Alaverdi of eBioscience Corporation, +1-858-642-2058,
noosheen.alaverdi@ebioscience.com